CDK4 and neoplasm: There is good evidence that some of the long‐term outcomes are linked, in particular, senescent cells can secrete a variety of factors that engage the immune system (Xue et al, 2007; Krizhanovsky et al, 2008; Kang et al, 2011; Acosta et al, 2013), and this senescence phenotype contributes to the ability of CDK4/6 inhibition to sensitize tumours to immune checkpoint blockade (Jerby‐Arnon et al, 2018; Ruscetti et al, 2018, 2020).